Symbiotec Pharmalab has received the U.S. FDA Establishment Inspection Report for its manufacturing facility located in Pithampur, Madhya Pradesh, with a Voluntary Action Indicated (VAI) status.

Regulatory outcome details

The VAI classification is issued by the U.S. Food and Drug Administration following an establishment inspection and indicates that while observations may have been noted during the inspection, no regulatory action is required by the agency. The designation reflects an acceptable compliance standing for the inspected facility.

The inspection was conducted at the company’s manufacturing facility at Pithampur from August 10, 2026 to August 14, 2026. The report was formally communicated to the exchanges on September 29, 2026.

Significance of the VAI classification

A VAI status from the U.S. FDA is considered a favourable regulatory outcome for pharmaceutical manufacturing sites. It signals that the facility meets the agency's compliance standards without necessitating mandatory corrective actions, which is a prerequisite for continued supply of products to the U.S. market.

Symbiotec Pharmalab targets 20-25% revenue and EBITDA growth for FY27, with new CDMO and injectable revenues anticipated to commence in the second half of the fiscal year.

The company released the audio recording of its earnings conference call for the quarter ended June 30, 2026 (Q1FY27). The call, held on September 22, 2026, discussed operational performance, including a 53% year-on-year decline in consolidated net profit to ₹140.6 million. The Board approved unaudited financial results on September 21, 2026.

Financial Performance

Consolidated revenue from operations increased to ₹2,181.5 million in Q1FY27, compared to ₹2,031.7 million in the corresponding period last year. However, total expenses rose significantly to ₹2,009.6 million from ₹1,609.9 million, primarily due to higher employee benefit expenses and other operating costs.

Standalone results showed a different dynamic, with net profit surging to ₹470.1 million from ₹445.1 million in Q1FY26. This increase was largely driven by a significant rise in other income, which stood at ₹195.5 million compared to ₹114.7 million in the prior year. Standalone revenue from operations grew modestly to ₹2,108.4 million.

New data confirms that consolidated EBITDA for Q1FY27 stood at ₹592 million, down from ₹623 million in Q1FY26. The EBITDA margin contracted to 28.05% from 30.50% in the previous year, reflecting pressure from rising operational costs despite top-line growth.

Impact of New Business Investments

The sharp decline in consolidated profitability is attributed to heavy investments in new business verticals that are not yet generating revenue. The investor presentation highlights that ₹23.2 million in operating expenses and ₹11.6 million in depreciation and amortization were incurred specifically for these new initiatives in Q1FY27. Management stated that these expenses will continue at similar levels for the next two to three quarters, impacting profitability until associated revenues begin in the next 6 to 12 months.

While the core API business maintained steady growth, with revenue rising 6% to ₹2,153 million and EBITDA growing 9% to ₹658 million, the group-wide EBITDA margin contracted from 29% to 21%. Management expects revenue generation from these new businesses, including Complex Injectables and Biotech CDMO services, to commence within the next 6–12 months. Specifically, milestone cash flows and some small revenues from Biotech CDMO services are expected in the second half of FY27, with significant revenues from new businesses anticipated next year.

Operational Updates and Regulatory Milestones

Symbiotec successfully completed four major regulatory audits recently:

• EUGMP audits in Rau and Pithampur plants in March 2026, with approval certification received for both.
• USFDA audit in March-April 2026 at the Rau plant, where an Establishment Inspection Report (EIR) was received.
• USFDA audit in August 2026 at the Pithampur plant, with the EIR awaited.

In Complex Injectables, the company filed its first Abbreviated New Drug Application (ANDA) for a Dual Chamber Vial (DCV) product in September 2026, marking the first generic filing for this product in the US market. A second ANDA filing is scheduled for early Q4 FY27. Additionally, a licensing agreement for the distribution of two DCV products in the US is at an advanced stage.

In Biotech CDMO Services, Symbiotec has onboarded new customers and secured a 10-year take-or-pay agreement with a US-based alternate protein player. A similar term sheet with a European player is also advanced. For Bio-Pharmaceutical Insulin Drug Substance, a 5-year take-or-pay agreement is in place, with regulatory approval filing expected in Q4 FY27. The company also co-signed a term sheet with a large U.S.-based pharma MNC; the definitive agreement is at an advanced stage and expected in early Q3 FY27.

Capital Expenditure and Debt Position

As of June 30, 2026, gross capital expenditure stood at ₹1,475 million, with an estimated total of ₹1,666 million expected by the end of FY27. Only 39% of this total gross capex is currently generating revenue, with 61% allocated to new projects such as Dual Chamber Vials and CDMO facilities. Q1FY27 gross capex invested was approximately ₹68 million. Looking ahead, the company plans to invest ₹200 crore to ₹250 crore annually in CapEx for the next two to three years, with potential acceleration based on opportunities and customer contributions.

Net debt stood at approximately ₹398 million as on June 30, 2026. Post IPO proceeds, net debt reduced to approximately ₹326 million as on September 20, 2026.

Guidance and Outlook

For the current fiscal year, Symbiotec targets 20% revenue growth and 25% EBITDA growth on a consolidated basis, with a potential ±5% variance due to global uncertainty. The company expects API business gross margins to remain around 60%, with EBITDA margins close to 30%, driven by backward integration and a focus on regulated markets and valuable products.

What the Numbers Show

The divergence between consolidated and standalone profitability highlights the impact of inter-company transactions and subsidiary performance. While standalone other income contributed substantially to the parent company’s bottom line, consolidated net profit was pressured by rising operational costs across the group. Employee benefit expenses increased to ₹464.2 million from ₹351.4 million, reflecting potential wage revisions or headcount growth.

Furthermore, the capital intensity of the expansion is evident. As of June 30, 2026, gross capital expenditure stood at ₹1,475 million, with an estimated total of ₹1,666 million expected by the end of FY27. Only 39% of this total gross capex is currently generating revenue, with 61% allocated to new projects such as Dual Chamber Vials and CDMO facilities. The guidance for continued high CapEx spending of ₹200-250 crore annually suggests that margin pressure may persist in the short term until the new capacity achieves utilization.

Earnings Call Details

The management team participating in the discussion includes Anil Satwani (Promoter & CMD) and Raghavender Ramachandran (Chief Financial Officer). The call was hosted by JM Financial Institutional Securities Limited.

Investors can access the audio recording via the company's investor relations website. The recording covers the operational and financial performance discussed during the session.

Participants were advised to dial in 10 minutes prior to the scheduled start time. The company has stated that no unpublished price-sensitive information will be shared during the call.

Regulatory Compliance

The intimation regarding the audio recording is issued pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The trading window for dealing in the company’s securities remains closed until 48 hours from the announcement. Further information is available on the company’s investor relations website.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE899I01028/9e29ea3f-c848-4fe7-b2a3-19be93d396c4.pdf